Characterization of GATA3 mutational status in early-stage breast cancer patients from Slovenia
Eurasian Journal of Medicine and Oncology · 03.06.2026 · 10 (4) · 026140153
DOI: 10.36922/ejmo026140153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 03.06.2026. Verfasst von Bojana Crnobrnja und 6 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
GATA3 is a zinc-finger transcription factor essential for luminal cell fate specification in the mammary gland and a well-established marker of estrogen receptor (ER)-positive breast cancer (BC). High GATA3 expression characterizes the luminal A subtype and is associated with a favorable prognosis, while reduced expression and somatic mutations in its zinc-finger and C-terminal domains have been linked to aggressive tumor behavior. However, the molecular determinants of GATA3 loss in early-stage BC remain poorly understood.
Objective
To characterize GATA3 mutational status in early-stage breast cancer patients.
Methods
We characterized GATA3 protein expression by immunohistochemistry and assessed somatic mutations in exons 2–6 in a prospective cohort of 60 early-stage BC patients from Slovenia. We additionally performed a comprehensive analysis of somatic variations across the GATA3 gene using COSMIC data and evaluated the structural impact of single-nucleotide variants (SNVs) on GATA3 protein stability using in silico tools.
Results
Most tumors (90%) exhibited high GATA3 immunoreactivity, which correlated significantly with ERα expression (p = 0.006). No somatic mutations were identified in exons 2–6 in tumors with absent or low GATA3 expression, suggesting that epigenetic mechanisms such as promoter hypermethylation drive expression loss in early-stage disease. Among 469 COSMIC-cataloged somatic variations, frameshift mutations predominated, and exon 6 harbored the highest mutational burden (55.88%). In silico analysis revealed that 51.46% of SNVs exerted destabilizing effects on GATA3 structure, predominantly within the zinc-finger 2 domain. Two variants, P42L and S93F, exhibited stabilizing effects warranting further functional investigation.
Conclusion
Our findings provide characterization of GATA3 in early-stage BC from Slovenia and implicate epigenetic silencing as an alternative mechanism of GATA3 inactivation.
Zitieren
APA
Crnobrnja, B., Büdefeld, T., Glavač, D., Jezernik, G., Jurgec, S., Takač, I., & Potočnik, U. (2026). Characterization of GATA3 mutational status in early-stage breast cancer patients from Slovenia. Eurasian Journal of Medicine and Oncology, 10(4), 026140153. https://doi.org/10.36922/ejmo026140153
Vancouver
Crnobrnja B, Büdefeld T, Glavač D, Jezernik G, Jurgec S, Takač I, et al. Characterization of GATA3 mutational status in early-stage breast cancer patients from Slovenia. Eurasian Journal of Medicine and Oncology. 2026;10(4):026140153. doi:10.36922/ejmo026140153
BibTeX
@article{Crnobrnja2026,
author = {Crnobrnja, Bojana and Büdefeld, Tomaž and Glavač, Damjan and Jezernik, Gregor and Jurgec, Staša and Takač, Iztok and Potočnik, Uroš},
title = {Characterization of GATA3 mutational status in early-stage breast cancer patients from Slovenia},
journal = {Eurasian Journal of Medicine and Oncology},
year = {2026},
volume = {10},
number = {4},
pages = {026140153},
doi = {10.36922/ejmo026140153}
}
EUVIMED